Objectives.-Stage I, grade 1 endometrial cancers have low recurrence rates and often do not receive adjuvant therapy. We compared recurrent cases to matched non-recurrent controls to evaluate for molecular markers associated with higher risk of recurrence. Methods.-A case-control study including all cases of recurrent stage I, grade 1 endometrioid endometrial cancer at one institution in a ten-year period. Cases were matched to controls by age, BMI, weight and stage. Molecular testing and immunohistochemistry were performed on archival tumor specimens: microsatellite instability (MSI-H), mismatch repair status, POLE mutational status, and next-generation sequencing.
Gynandroblastoma is an extremely rare primary tumor of the ovary showing morphological evidence of both female (granulosa cell tumor) and male (Sertoli or Sertoli-Leydig tumor) differentiation. We report an unusual case of a 32-year-old female who presented with hyperandrogenism and was found on imaging to have concurrent ovarian and renal masses. Following surgical excision, the ovarian mass was diagnosed as gynandroblastoma, which consisted of 45% juvenile granulosa cell tumor and 55% intermediately differentiated Sertoli-Leydig tumor. The renal mass was diagnosed as a conventional renal clear cell carcinoma. Gynandroblastoma, especially with juvenile granulosa cell tumor, is an extremely rare ovarian tumor. Concurrent gynandroblastoma with another malignant neoplasm has not been reported in the literature.
PCNs rarely arise in the intracranial compartment. Intracranial PCN may be the initial presentation of MM. Anecdotally, blastic morphology appears to manifest more aggressive behavior.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.